CARBIDOPA AND LEVODOPA Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Carbidopa And Levodopa, and when can generic versions of Carbidopa And Levodopa launch?
Carbidopa And Levodopa is a drug marketed by Accord Hlthcare, Alembic, Apotex, Impax Labs, Kv Pharm, Mylan, Rubicon, Sciegen Pharms Inc, Sun Pharm Inds, Rising, Sun Pharm, Actavis Elizabeth, Ani Pharms, Apotex Inc, Aurobindo Pharma Ltd, Dr Reddys Labs Sa, SCS, Watson Labs, and Zydus Pharms. and is included in twenty-eight NDAs.
The generic ingredient in CARBIDOPA AND LEVODOPA is carbidopa; levodopa. There are eighteen drug master file entries for this compound. Thirty-five suppliers are listed for this compound. Additional details are available on the carbidopa; levodopa profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Carbidopa And Levodopa
A generic version of CARBIDOPA AND LEVODOPA was approved as carbidopa; levodopa by DR REDDYS LABS SA on August 28th, 1992.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for CARBIDOPA AND LEVODOPA?
- What are the global sales for CARBIDOPA AND LEVODOPA?
- What is Average Wholesale Price for CARBIDOPA AND LEVODOPA?
Summary for CARBIDOPA AND LEVODOPA
| US Patents: | 0 |
| Applicants: | 19 |
| NDAs: | 28 |
| Finished Product Suppliers / Packagers: | 31 |
| Raw Ingredient (Bulk) Api Vendors: | 7 |
| Clinical Trials: | 185 |
| Drug Prices: | Drug price information for CARBIDOPA AND LEVODOPA |
| DailyMed Link: | CARBIDOPA AND LEVODOPA at DailyMed |
Recent Clinical Trials for CARBIDOPA AND LEVODOPA
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| The Affiliated Hospital of Qingdao University | Phase 1 |
| Bronx VA Medical Center | Phase 1 |
| VistaGen Therapeutics, Inc. | Phase 2 |
Pharmacology for CARBIDOPA AND LEVODOPA
| Drug Class | Aromatic Amino Acid |
US Patents and Regulatory Information for CARBIDOPA AND LEVODOPA
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dr Reddys Labs Sa | CARBIDOPA AND LEVODOPA | carbidopa; levodopa | TABLET;ORAL | 073607-001 | Aug 28, 1992 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Ani Pharms | CARBIDOPA AND LEVODOPA | carbidopa; levodopa | TABLET;ORAL | 073587-003 | Jun 29, 1995 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Sciegen Pharms Inc | CARBIDOPA AND LEVODOPA | carbidopa; levodopa | TABLET;ORAL | 214092-002 | May 7, 2021 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
EU/EMA Drug Approvals for CARBIDOPA AND LEVODOPA
| Company | Drugname | Inn | Product Number / Indication | Status | Generic | Biosimilar | Orphan | Marketing Authorisation | Marketing Refusal |
|---|---|---|---|---|---|---|---|---|---|
| Amneal Pharma Europe Ltd | Numient | levodopa, carbidopa | EMEA/H/C/002611 Symptomatic treatment of adult patients with Parkinson’s disease |
Withdrawn | no | no | no | 2015-11-19 | |
| >Company | >Drugname | >Inn | >Product Number / Indication | >Status | >Generic | >Biosimilar | >Orphan | >Marketing Authorisation | >Marketing Refusal |
